Chronic Pain Australia is dedicated to reducing the unnecessary suffering and isolation caused by chronic pain in the Australian community. To that end, we aim to promote and facilitate research that will contribute to the evidence base, and improve our knowledge and understanding of chronic pain prevention and management, as well as the social barriers and other challenges related to living with chronic pain.
In an effort to ensure that the research we facilitate is ethical and in the best interest and to minimise harm to people experiencing or impacted by chronic pain. Chronic Pain Australia typically promotes only research studies that have ethics approval from a university or other recognised authority’s Human Research Ethics Committee (HREC).
Once received, your request will be reviewed by our Research Committee and/or the Chronic Pain Australia Board of Directors, who will let you know of the outcome via email. While we always aim to respond at our earliest convenience (usually within fourteen working days), there are occasional delays as we depend largely on the work of volunteers.
If you are willing and able to support the ongoing work of Chronic Pain Australia, we would love for you to become a member of our organisation. If membership is not something you can commit to at this time, please consider making a tax-deductible donation to our organisation by clicking here.
Thank you in advance for your generous support.
Chronic Pain Australia would also be keen to disseminate the results of your research via our website and social media channels – so please keep us informed on the progress of your research and the outcomes.
Good luck with your research!
Research participation opportunities:
Understanding the use of pain management and other health services by people living with chronic pain - study recruitment open until all participant places are filled
A brief description of the study:
We are looking for participants for a study examining how people living with chronic pain access to health services. We would like to explore the services people with chronic pain currently use as well as barriers to service access or attitudes around the effectiveness of different services. The research study aims to gain an understanding of how different services are used for pain management, and what barriers or enablers may hinder or help people to access them. We hope that this will help inform the planning of future services for people with chronic pain. The scope and interview questions were informed by previous work, both nationally and internationally, including results from the National Pain Survey.
The study involves taking part in a 1-hour interview, either by telephone or in-person at the National Drug and Alcohol Research Centre at 22-32 King Street, Randwick, Sydney (participant preference).
Participant selection criteria:
The research is looking to recruit people who meet the following:
• have been living with chronic pain for at least 3 months
• able to complete a telephone or in-person interview in English without assistance
Participants who meet the following criteria will be excluded from the study:
• under the age of 18 years old
• pain is related to cancer
• receiving palliative care services.
Remuneration: Participants will be reimbursed $20 for their time.
Researcher and who to contact if you are interested in participating:
Bachelor Health Science (Hons), MPH
This project has been reviewed and approved by Sydney Uni Ethics 2020/557, 17/9/20. It has also been reviewed by the Chronic Pain Australia Research Subcommittee.
The QUEST initiative - QUality of life Evaluation STudy: Assessing Health-Related Quality of Life in patients receiving Medicinal Cannabis - study recruitment open until 31st March 2022
The Quality of life Evaluation Study (QUEST Initiative) conducted by researchers at the University of Sydney aims to be the world’s largest longitudinal clinical study investigating the health-related quality of life and the health economic impact on patients with chronic disease accessing medicinal cannabis.
Patients accessing medicinal cannabis generally have a range of conditions and symptoms that impact their quality of life. This clinical study sets out to better understand and measure how these conditions and symptoms affect a patient’s quality of life over time while they are accessing medicinal cannabis as a treatment option.
The QUEST Initiative will commence recruitment of eligible patients in November 2020. Participants will access discounted cannabinoid medications in the form of an oral solution.
For more information please visit https://www.thequestinitiative.com
Participant information can be downloaded here: QUEST Study - Participant Information Sheet
A brief description of the study:
Study aim: This research will evaluate patient reported outcomes (PROs) in patients being prescribed medicinal cannabis under the Special Access Schemes across clinics within Australia and the UK. The findings from this study have potential to be integral to treatment assessment and recommendations for chronic pain sufferers and other patients with health indicators for accessing medicinal cannabis.
Primary objectives: Describe changes in PROs (HRQL, pain, fatigue, sleep, anxiety, depression) from baseline to 3-months for a large cohort receiving medicinal cannabis.
Secondary objectives: (1) Describe changes in PROs (HRQL, pain, fatigue, sleep, anxiety, depression, functioning) from baseline over 12-months. (2) Compare differences in PROs between patients accessing medicinal cannabis across different health condition groups, including, but not limited to: Chronic Pain primary; Multiple Sclerosis; Epilepsy; Parkinson’s Disease; and Cancer. 3 months for a large cohort receiving medicinal cannabis.
Exploratory objectives: (1) Explore which individuals are more likely to have lower symptom burden and greater HRQL. (2) Explore associations between the PROs, with the hypothesis that high symptom burden is associated with poorer HRQL. (3) Explore associations between the PROs over time, with the hypothesis that lower symptom burden is associated with reduced healthcare resource use, and reduced use of opioids and other prescribed medications for managing symptoms.
Hypotheses: (1) PROs will improve from baseline to 3-months in patients accessing medicinal cannabis. (2) Improvements in PROs at 3 months will be maintained over a 12-month period. (3) No differences in improvements in PROs between patients being treated for different conditions (e.g. chronic pain, Multiple Sclerosis, Epilepsy, Parkinson’s Disease, or Cancer).
A brief description of potential benefits for people with chronic pain:
• Access to regular reporting/tracking of individualized quality of life changes via reports made available to participants prescribing doctors.
• Opportunity to be part of a world-first quality-of-life study conducted by a leading academic institution.
• Subsidised cost of medication
Participant selection criteria:
Inclusion criteria: All the following must be satisfied for enrolment in the study:
• adult patients (aged ≥18 years)
• patient has been identified as eligible to receive medicinal cannabis under the special access scheme (or equivalent in other countries and jurisdictions) by a doctor at participating centres registered to prescribe medicinal cannabis
• patient is able to read and understand English
• patient is able to provide informed consent
• patient has not started medicinal cannabis therapy, or the patient started medicinal cannabis therapy within the previous 2 days (we expect no therapeutic benefit within 2 days)
• patient has not received prescribed medicinal cannabis therapy in the previous 4 weeks (excluding previous 2 days)
• patient has a life-expectancy >3 months
Exclusion criteria: Patients will be excluded from the study if any of the following criteria apply:
• are unconscious or confused
• have cognitive impairment
• are pregnant
• are unable to speak, read and/or write in English
• are denied access to medicinal cannabis under the relevant Special Access Scheme for their country of registration
• are unable to provide informed consent
• are already receiving medicinal cannabis treatment for more than 2 days
• have received prescription medicinal cannabis within the last 4 weeks (excluding previous 2 days)
Researcher and who to contact if they are interested in participating:
Dr. Leon N. Warne
BSc(Biol), BBiomedSc(Hons1), BSc, BVMS, MVS, MANZCVS, Diplomate ACVAA, PhD
Senior Lecturer | College of Science, Health, Engineering and Education (SHEE) | Murdoch University
Document of the entire project team can be found here.